Waters Corporation has introduced the Waters™ SELECT SERIES™ MRT, a high-resolution mass spectrometer that combines Multi Reflecting Time-of-Flight (MRT) technology with both enhanced DESI and new MALDI imaging sources. Together, these technologies enable scientists to explore molecular structure and function through the precise identification and localization of individual molecules in samples, with a unique combination of speed, resolution, and mass accuracy.
For example, a scientist researching how an investigational oncology drug interacts with its intended target, such as a specific brain tumour receptor, can now do so much faster, at speeds up to 10Hz without compromising mass accuracy or resolution.
The SELECT SERIES MRT platform is the basis for the next generation of Waters’ high-resolution mass spectrometers. It is the first commercially available instrument of its kind that is capable of attaining 200,000 Full Width Half Maximum (FWHM) resolution and part-per-billion mass accuracy independent of scan speed. The superior performance of the SELECT SERIES MRT allows scientists to get the highest quality mass spectrometry data and information faster than any commercial mass spectrometer on the market todayii. The new Multi Reflecting Time-of-Flight technology features an extended flight path of almost 50 meters to give scientists a much clearer picture of structural information, including fine isotope structure.
“The Waters SELECT SERIES MRT opens the door to a greater understanding of molecules and their mechanisms of action in numerous scientific fields,” explained Dr. Udit Batra, CEO and President, Waters Corporation. “The clarity of images produced by this instrument can yield profoundly important molecular information to scientists in research areas such as targeted therapeutics, to provide insights and enable deep biological discoveries.”
DESI XS and MALDI imaging on a single MRT platform
The first application of the SELECT SERIES MRT unlocks the potential of MS imaging using DESI and MALDI ionization. DESI is a direct-from-sample, soft ionization technique performed under ambient environmental conditions, requiring no prior sample preparation. It provides imaging information about the biochemical distribution of small molecule drugs, lipids, and naturally occurring metabolites within a slice of tissue or on other sample surfaces after just a single measurement. Scientists are applying DESI to research breast and ovarian cancer, to study drug metabolism and pharmacokinetics (DMPK), to investigate the function of key metabolites in natural products in traditional medicines, and to get a closer look at the biotransformation of bacterial colonies after gene modifications.
Featuring a new high-performance sprayer and a heated transfer line, the advanced DESI XS source delivers new levels of usability, image clarity and sensitivity at high speed, bringing more accessible imaging to scientists through mass spectrometry data.
For scientists interested in conducting MALDI imaging experiments, the SELECT SERIES MRT is available with a newly designed MALDI source. MALDI is an ideal complementary technique for the imaging of biological molecules such as peptides and can visualize tissue sections at spatial resolutions of less than 10 microns. Taken together, the combination of imaging sources gives researchers the means to generate fine spatial information and morphological detail for biological samples and even visualize brain vasculature.
Customer shipments of the SELECT SERIES MRT are expected to begin in the fourth quarter of this year.
Thermo Fisher Scientific, Advanced Electrophoresis Solutions agree to combine essential protein separation techniques with mass spectrometry
, /in E-News /by panglobalThermo Fisher Scientific and Advanced Electrophoresis Solutions (AES), specialists in protein imaging technologies, have agreed to combine essential protein separation techniques with mass spectrometry (MS) to advance therapeutic protein development through streamlined characterization.
Together, the companies will promote Thermo Fisher’s expertise as a leading provider of mass spectrometry technology for biopharma and proteomics applications, and AES’ ability to provide high performing whole column imaging detection capillary electrophoresis systems for protein separation, quantification and characterization. The companies will highlight the strengths of their technologies when coupled for protein analysis to provide laboratories with new and advanced biopharmaceutical capabilities that will enable greater insight into results generated by Imaged Capillary Isoelectric Focusing (iCIEF) protein separation. This will be of particular benefit to scientists working in the areas of biopharma, clinical, food analysis and academia.
“Protein separation, purification and analysis are crucial components in biotherapeutic development, but the process can be complex and challenging,” said Eric Grumbach, director, pharma/biopharma, chromatography and mass spectrometry, Thermo Fisher Scientific. “While mass spectrometry does provide high-sensitivity and high-resolution protein mass information, there are cases where insight from a different angle is required. Through this agreement we will pair our technology with more widely used and essential separation tools previously not routinely coupled to MS to make protein variant identification easier and more accurate to advance high-quality information and scientific knowledge.”
Tiemin Huang, CEO, AES, said: “There is a growing demand for proteomics and protein characterization, driven by the rise of personalized medicine, so it’s important that the best combination of tools are available to progress our understanding and research in this important field. By working side-by-side with Thermo Fisher to combine high resolution accurate mass-mass spectrometry (HRAM-MS) with alternative protein separation techniques, we will support our customers to achieve more precise analyses that will play a significant role in the continued development of effective therapeutics.”
Selux Diagnostics receives additional $14.6 million in BARDA funding after successfully completing first clinical trial
, /in E-News /by panglobalSelux Diagnostics, which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, has been awarded an additional $14.6 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.
BARDA modified the cost sharing contract, raising the Government’s cost share of $45 million to a total level of $60.8 million if all options are exercised. This additional funding will allow Selux to continue implementing its microbiology roadmap and commercialize its Next Generation ‘Phenotyping’ (NGP) platform for rapid antimicrobial susceptibility testing (AST).
Selux received the latest round of funding after successfully achieving a key milestone: completion of its first clinical trial. The trial confirmed the platform’s ability to accurately provide rapid AST results from cultured isolates with a broad antibiotic menu all within the same shift – the patient’s most vulnerable window and critical period of infection. Selux will now submit the clinical trial results to the U.S. Food and Drug Administration (FDA), the next step in clearing the way for the commercialization of the innovative NGP platform.
Antibiotic resistance
“A global crisis of antibiotic resistance requires innovation to save lives, and we believe this next generation technology represents the future backbone of microbiology,” said Steve Lufkin, CEO of Selux. “Our plan is to build on the success of this first clinical study and turn our attention to the next phase of product development to speed the time to targeted antibiotic treatment further, preserving the lifesaving power of antibiotics for future generations.”
The Centers for Disease Control and Prevention calls antibiotic resistance one of the “biggest public health challenges of our time” – a growing problem that is not only deadly but extremely costly. According to a January report by the CDC and the University of Utah, multi-drug resistant pathogens are estimated to cost the U.S. more than $4.6 billion annually.
The proprietary Selux technology uniquely provides targeted therapy results days faster than the current standard of care providing actionable information to inform patient treatment for all Infectious Diseases. Selux’s NGP platform provides unprecedented speed-to-results and breadth of menu while meeting the accuracy, throughput, and cost effectiveness requirements of clinical microbiology laboratories and integrated healthcare systems.
The Selux platform is an investigational device, limited by U.S. federal law to investigational use.
INTEGRA Biosciences takes significant step towards sustainability
, /in E-News /by panglobalINTEGRA Biosciences has made significant progress towards its goal of minimizing its ecological footprint with the installation of new photovoltaic systems at the company’s US facilities in Hudson, NH. These systems will provide 77 percent of the total energy requirement for both the company’s US headquarters and production centre, saving as much CO2 as 2900 cars or 2300 single-family homes produce in the USA each year.
INTEGRA first introduced photovoltaic systems at its global headquarters in Zizers, Switzerland, in 2019. Combined with extensive use of Swiss hydropower, this ensures that the Zizers site – including heating and cooling – is run entirely with renewable energy. Expanding this approach to its US facilities, INTEGRA has now completed the installation of almost 1500 panels with double-sided solar cells on the roofs of its two buildings in Hudson. Capable of producing 817,000 kWh per year, they are expected to produce more than 19 million kWh over their service life.
This latest step is part of the company’s overall commitment to sustainability, which also includes, promoting the recycling of single-use consumables, encouraging employees to use sustainable forms of transport wherever possible, and using sustainable energy supplies.
Ursula Leuthold, INTEGRA’s dedicated sustainability coordinator, commented: “We constantly review our processes to make them more environmentally friendly. By commissioning these new solar power systems in the USA, we have now reached our next important milestone towards sustainability.”
Soluble Transferrin Receptor (sTfR) assays for IMMAGE®, ADVIA® and other Clinical Chemistry analyzers
, /in Product News /by 3wmediaTRIMERO Diagnostics offers IVD CE marked assays for testing Soluble Transferrin Receptor (sTfR).
Cytiva Sera-Mag Select™ reagent
, /in Product News /by panglobalRunning a sequence through an instrument is expensive and time consuming.
UV Smart aims to provide healthcare facilities all over the world with validated UV-C disinfection methods to ensure a safer environment for patients and healthcare professionals.
, /in E-News, Product News /by panglobalDisinfection with high-energy UV-C light has been proven safe and effective. UV Smart makes this technology easily applicable for the validated disinfection of medical instruments and equipment. The result: a safer environment for healthcare professionals and their patients.
Cherry picking 2D barcoded sample tubes
, /in Product News /by panglobalZiath has posted a new video that shows how its Mohawk semi-automated tube selector is a productive and versatile tool for cherry picking tubes from multiple racks.
In the new video, product manager Avash Anderson demonstrates how the Mohawk provides secure and accurate picking of individual 2D-barcoded tubes from 96-place SBS format racks – quickly and easily. Using Ziath’s web-based DP5 software, Avash also demonstrates how simple it is to load a picking list, retrieve the desired tubes and then verify them on a connected 2D tube reader.
Trying to extract a single tube from a rack can be difficult and doing so manually can lead to positional errors. By using software to control 96 individual solenoids, the Mohawk can lift one, two or up to sixteen individual tubes at a time, making it easy to remove them from the rack and place in a subsidiary rack or other tube device.
The pins to be selected can be set in a “Pick List” which can be generated from the onscreen graphical representation of the Mohawk deck or from an Excel spreadsheet. The Mohawk is able to operate with both thawed and frozen tubes and can even generate pick lists including tubes that are contained in multiple racks.
To watch this new video, visit: https://youtu.be/ktLE6umE2bY
WESAIL COVID-19 Ag Test Kit (self-testing) is now 4th in the world TUV CE0123
, /in Product News /by 3wmediaThis product can offer result in 15 minutes. With simple steps, individuals can complete the test in any settings, such as home, school, border, etc. The test can detect COVID-19 wild-type virus and 30+ mainstream variants, which helps individuals make informed decisions and lower the risk of transmission.
Porvair takes strain out of microplate sealing with autocapper
, /in Product News /by panglobalPorvair Sciences has released its next generation AutoCapper electronic sealer – a versatile device designed to take the strain out of applying friction sealing caps to a wide range of microplates.
Built to quickly and securely seal 96-well deep well microplates as standard, the AutoCapper is also compatible with shallow well and 24- and 48-well deep well plate formats using a range of supplied adapter blocks.
Small enough to fit on most lab benches, the AutoCapper has been designed to do all the hard work for you. A plate with its attendant cap mat is simply placed in the drawer and pushed firmly shut. From then on, the sophisticated electronics take over, forcing the cap mat down into each well by applying consistent, even pressure. With just a touch of a button, the powerful, yet smooth operating mechanism makes single action sealing of microplates quick and simple, therefore removing any risk of Repetitive Strain Injury (RSI).
The AutoCapper is the perfect solution for laboratories looking for an affordable device that makes the entire plate sealing process faster and more reproducible.
Waters sets new standard in high resolution mass spectrometry with SELECT SERIES Multi Reflecting Time-of-Flight platform
Laboratory, /in Product News /by panglobalWaters Corporation has introduced the Waters™ SELECT SERIES™ MRT, a high-resolution mass spectrometer that combines Multi Reflecting Time-of-Flight (MRT) technology with both enhanced DESI and new MALDI imaging sources. Together, these technologies enable scientists to explore molecular structure and function through the precise identification and localization of individual molecules in samples, with a unique combination of speed, resolution, and mass accuracy.
For example, a scientist researching how an investigational oncology drug interacts with its intended target, such as a specific brain tumour receptor, can now do so much faster, at speeds up to 10Hz without compromising mass accuracy or resolution.
The SELECT SERIES MRT platform is the basis for the next generation of Waters’ high-resolution mass spectrometers. It is the first commercially available instrument of its kind that is capable of attaining 200,000 Full Width Half Maximum (FWHM) resolution and part-per-billion mass accuracy independent of scan speed. The superior performance of the SELECT SERIES MRT allows scientists to get the highest quality mass spectrometry data and information faster than any commercial mass spectrometer on the market todayii. The new Multi Reflecting Time-of-Flight technology features an extended flight path of almost 50 meters to give scientists a much clearer picture of structural information, including fine isotope structure.
“The Waters SELECT SERIES MRT opens the door to a greater understanding of molecules and their mechanisms of action in numerous scientific fields,” explained Dr. Udit Batra, CEO and President, Waters Corporation. “The clarity of images produced by this instrument can yield profoundly important molecular information to scientists in research areas such as targeted therapeutics, to provide insights and enable deep biological discoveries.”
DESI XS and MALDI imaging on a single MRT platform
The first application of the SELECT SERIES MRT unlocks the potential of MS imaging using DESI and MALDI ionization. DESI is a direct-from-sample, soft ionization technique performed under ambient environmental conditions, requiring no prior sample preparation. It provides imaging information about the biochemical distribution of small molecule drugs, lipids, and naturally occurring metabolites within a slice of tissue or on other sample surfaces after just a single measurement. Scientists are applying DESI to research breast and ovarian cancer, to study drug metabolism and pharmacokinetics (DMPK), to investigate the function of key metabolites in natural products in traditional medicines, and to get a closer look at the biotransformation of bacterial colonies after gene modifications.
Featuring a new high-performance sprayer and a heated transfer line, the advanced DESI XS source delivers new levels of usability, image clarity and sensitivity at high speed, bringing more accessible imaging to scientists through mass spectrometry data.
For scientists interested in conducting MALDI imaging experiments, the SELECT SERIES MRT is available with a newly designed MALDI source. MALDI is an ideal complementary technique for the imaging of biological molecules such as peptides and can visualize tissue sections at spatial resolutions of less than 10 microns. Taken together, the combination of imaging sources gives researchers the means to generate fine spatial information and morphological detail for biological samples and even visualize brain vasculature.
Customer shipments of the SELECT SERIES MRT are expected to begin in the fourth quarter of this year.